2021

1. Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A,Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K,Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H,
Japan Urological Oncology Group: Impact of the objective response to and number of cycles of platinumbased first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treatedwith pembrolizumab. Int J Urol. 2021 Dec; 28 (12): 1261-1267. [5y-IF: 3.011]

2. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N: Primary renal
leiomyosarcoma with a tumor thrombus in the inferior vena cava. IJU Case Rep. 2021 Nov; 5 (1): 66-69.
[5y-IF: N/A]
3. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K,Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: Are simple verbal instructions
sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot
scanning proton therapy? BJR Open. 2021 Nov; 3 (1): 20210064. [5y-IF: N/A]
4. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K,
Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: Are simple verbal instructions
sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot
scanning proton therapy? BJR Open. 2021 Nov; 3 (1): 20210064. [5y-IF: N/A]
5. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, Shinohara N:
Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary
tract urothelial carcinoma. IJU Case Rep. 2021 Dec; 5 (2): 108-112. [5y-IF: N/A]

2022

1. Aydın A, Ahmed K, Abe T, Raison N, Van Hemelrijck M, Garmo H, Ahmed HU, Mukhtar F, Al-Jabir A,Brunckhorst O, Shinohara N, Zhu W, Zeng G, Sfakianos JP, Gupta M, Tewari A, Gözen AS, Rassweiler J,SkolarikosA, Kunit T, Knoll T, Moltzahn F, Thalmann GN, Lantz PowersAG, Chew BH, Sarica K, Shamim Khan M,Dasgupta P SIMULATE Trial Group: Effect of Simulation-based Training on Surgical Proficiency andPatient Outcomes: A Randomised Controlled Clinical and Educational Trial. Eur Urol. 2022 Apr; 81 (4):385-393. [5y-IF: 21.729]
2. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y,Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X,

Konno A, Shinohara N: Objective evaluation of laparoscopic surgical skills in wet lab training basedon motion analysis and machine learning. Langenbecks Arch Surg. 2022 Aug; 407 (5): 2123-2132. [5yIF: 3.116]
3. Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y,Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N: Late recurrence in patients with non-muscle-invasive
bladder cancer after 5-year cancer-free periods. Int J Urol. 2022 Oct; 29 (10): 1140-1146. [5y-IF: 3.011]
4. Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S,
Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, Shinohara N:
Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cellcarcinoma. Urol Oncol. 2022 Jan; 40 (1): 13.e19-13.e27. [5y-IF: 3.011]
5. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N: Outcomes of bacillus CalmetteGuérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in thesecond transurethral resection era. Int J Urol. 2022 Mar; 29 (3): 251-258. [5y-IF: 3.011]
6. Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami
K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T: Tolerability andtreatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal
dysfunction. Urol Oncol. 2022 Sep; 40 (9): 410.e11-410.e18. [5y-IF: 3.099]
7. Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume

H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami
A, Kuroiwa H: Bladder cancer prospective cohort study on high-risk non-muscle invasive bladdercancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHTstudy). Int J Urol. 2022 Jul; 29 (7): 632-638. [5y-IF: 3.011]

8. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai
S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara
N: Automatic assessment of laparoscopic surgical skill competence based on motion metrics. PLoS One.
2022 Nov; 17 (11): e0277105. [5y-IF: 4.069]

9. Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T,Tsukahara T, Kanaseki T, Shinohara N, Torigoe T: GRIK2 is a target for bladder cancer stem-like celltargeting immunotherapy. Cancer Immunol Immunother. 2022 Apr; 71 (4): 795-806. [5y-IF: 6.693]
10. Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T,Yamada T, Uemura M, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H,Fujimoto K: Real-world treatment patterns and oncological outcomes in early relapse and refractory disease
after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Int J Urol. 2022 Jul 20; doi:
10.1111/iju.14976. [5y-IF: 3.011]
11. Narita H, Takenaka J, Watanabe S, Abe T, Kudo K: Retroperitoneal Chronic Expanding Hematoma

Mimicking Malignancy on FDG PET/CT. Clin Nucl Med. 2022 Sep; 47 (9): e591-e593. [5y-IF: 7.77]
12. Oishi Y, Kitta T, Osawa T, Abe T, Shinohara N, Nosato H, Sakanashi H, Murakawa M: Diagnosis andLocalization of Prostate Cancer via Automated Multiparametric MRI Equipped with Artificial
Intelligence. Uro. 2022 2 (1): 21-29. [5y-IF: N/A]
13. Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe A, Shinohara N: Validationof an online application to identify potential immune-related adverse events associated with immune
checkpoint inhibitors based on the patient's symptoms. PLoS One. 2022 Mar; 17 (3): e0265230. [5y-IF: 4.069]
14. Suzuki M, Miyaji K, Watanabe R, Suzuki T, Matoba K, Nakazono A, Nakamaru Y, Konno A, Psaltis AJ,

Abe T, Homma A, Wormald PJ: Repetitive simulation training with novel 3D-printed sinus models forfunctional endoscopic sinus surgeries. Laryngoscope Investig Otolaryngol. 2022 Jul; 7 (4): 943-954. [5yIF: 2.857]
15. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari

H, Abe T, Shinohara N, Kudo K: Imaging findings of ovarian metastasis of primary renal cell
carcinoma: A case report and literature review. Radiol Case Rep. 2022 May; 17 (7): 2320-2327. [5y-IF:N/A]
16. Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K,Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M,Kakehi Y, Sugimoto M: Impact of health-related quality of life on repeat protocol biopsy compliance on
active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN
study. Urol Oncol. 2022 Feb; 40 (2): 56.e9-56.e15. [5y-IF: 3.099]
17. Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, TsuchiyaK, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y,Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: Comparative study of
postoperative complications after radical cystectomy during the past two decades in Japan: Radical
cystectomy remains associated with significant postoperative morbidities. Urol Oncol. 2022 Jan; 40 (1):11.e17-11.e25. [5y-IF: 3.099]
18. Yamagata Y, Abe T, IwaharaN, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R, OsawaT, Shinohara N: Metastatic neuroendocrine carcinoma of right adrenal glandsuccessfully treated withlaparoscopic adrenalectomy aftermultimodal therapy. IJU case reports. 2022 July; doi: https://doi.
org/10.1002/iju5.12511. [5y-IF: N/A]